Side-by-side · Research reference

EpitalonvsHGH 191AA

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/37 cited

BFDA-ApprovedHUMAN-REVIEWED0/75 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

01Mechanism of Action

Parameter

Epitalon

HGH 191AA

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Feedback intact?

—

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Antibody development

—

Rare — <2% develop binding antibodies, typically non-neutralizing

02Dosage Protocols

Parameter

Epitalon

HGH 191AA

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

—

Frequency

Once daily during a cycle

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Lower / starter dose

2.5 mg / day

—

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

FDA-approved / decades of RCT data

Duration

10–20 day cycles, 1–2× per year

Years (children until epiphyseal closure); indefinite (adult GHD)

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

—

Half-life

Hours (estimated)

—

Pediatric GHD

—

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

Adult GHD

—

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

Turner syndrome

—

0.045–0.050 mg/kg/day SQ

Idiopathic short stature

—

0.037 mg/kg/day SQ

AIDS wasting

—

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

Monitoring

—

IGF-1, glucose, thyroid function, bone age (children)

03Metabolic / Fat Loss Evidence

Parameter

Epitalon

HGH 191AA

Primary fat target

—

Visceral and subcutaneous adipose tissue

Mechanism

—

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

Effect on lean mass

—

Significant lean mass increase (protein synthesis, nitrogen retention)

Insulin sensitivity

—

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

IGF-1 elevation

—

Dose-dependent, significant — primary anabolic mediator

Glucose metabolism

—

Hyperglycemia risk, especially high doses (AIDS wasting)

Body composition

—

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

Clinical context

—

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

04Side Effects & Safety

Parameter

Epitalon

HGH 191AA

Injection site reaction

Mild irritation

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

Antibody formation

Not reported

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

Fluid retention / Edema

—

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

Glucose intolerance

—

Hyperglycemia, new-onset diabetes (anti-insulin effect)

Intracranial hypertension

—

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

Slipped capital femoral epiphysis

—

SCFE risk in children — limp, hip/knee pain (requires surgery)

Scoliosis progression

—

Rapid growth may unmask/progress scoliosis (monitor spine in children)

Hypothyroidism

—

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

Pancreatitis

—

Rare. Higher risk in children with certain syndromes (Prader-Willi).

Gynecomastia

—

Adolescent males (physiological during puberty, may be exacerbated)

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Relative Contraindications

Epitalon

·Family history of cancer

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

05Administration Protocol

Parameter

Epitalon

HGH 191AA

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

2. Injection site

SQ — abdomen preferred. Rotate sites.

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

3. Timing

Pre-sleep preferred to align with pineal axis.

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

5. Needle

29–31G, 4–8 mm insulin syringe.

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

6. Monitoring

—

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

06Stack Synergy

Epitalon

— no documented stacks

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms